septerna - Search News

News

Novo Nordisk Inks A Major Obesity Deal

The Wall Street Journal on MSN · 7h

Novo Nordisk and Septerna Strike $2.2 Billion Deal to Develop Obesity Pills

The deal with U.S. biotech Septerna will see the companies develop pills to treat obesity, type 2 diabetes and other cardiometabolic diseases.

Bloomberg on MSN · 23h

Novo Nordisk, Septerna Agree $2.2 Billion Obesity Pill Deal

Novo Nordisk A/S is partnering with US biotech Septerna Inc. on the development of oral pills for obesity in a deal potentially worth up to $2.2 billion.The two companies will start with four development programs that use different ways to potentially treat obesity,

Seeking Alpha on MSN · 1d

Novo Nordisk in pact with Septerna for oral obesity drugs

Septerna (SEPN) stock surges as Novo Nordisk (NVO) inks $2.2B deal to develop and commercialize oral obesity drugs. Read more here.

First patient treated with prime editing

From my colleague Jason Mast: The first ever patient has been treated with prime editing, a powerful technology for making ...

23h

Novo Nordisk, Septerna sign $2.2B deal to develop weight-loss pill

Pharmaceutical giant Novo Nordisk (NVO) inks a $2.2 billion deal with biotech company Septerna (SEPN) to develop a GLP-1 ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results